Research Keyword: efficacy

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Read More »

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice

mycolabadmin

This paper discusses why testing psychedelic therapies in clinical trials is more complicated than testing regular drugs. When people take psychedelics like MDMA or psilocybin, they clearly notice the effects, which makes it hard to keep the study ‘blinded’ (where neither patients nor researchers know who got the real drug). The author argues that for therapies combining drugs with counseling, this actually makes sense because the therapy itself is part of how the treatment works, not just a confounding factor. However, for stand-alone drug use, this unblinding is a real problem that makes it unclear whether the drug or people’s expectations caused the improvement.

Read More »

Benefits and risks of hair, skin, and nail supplements in older adults

mycolabadmin

This article reviews popular supplements that older adults, especially women, take to improve their hair, skin, and nails. While some supplements like nicotinamide show promise for sun-damaged skin, most lack strong evidence of benefit in healthy people. Important risks include biotin interfering with heart and thyroid tests, too much zinc causing copper deficiency, and excess vitamins A and E building up to toxic levels. Doctors should talk to older patients about these supplements and help them make informed decisions based on scientific evidence rather than marketing claims.

Read More »

Mushroom-Based Supplements in Italy: Let’s Open Pandora’s Box

mycolabadmin

Researchers tested 19 mushroom supplement products sold in Italy and found serious quality problems. Many supplements didn’t actually contain the mushroom species listed on their labels. Some products also contained toxic substances or inconsistent amounts of beneficial compounds. The study highlights the need for better regulation and manufacturing standards to ensure these popular health products are safe and effective.

Read More »

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

mycolabadmin

This study tests whether psilocybin (a psychedelic compound) combined with intensive therapy can help treat chronic PTSD better than therapy alone. Fifteen patients with PTSD will receive one dose of psilocybin alongside 12 therapy sessions completed over a single week. Researchers will track feasibility, safety, symptom improvements, and use wearable devices to monitor physiological changes. The results will help determine whether larger trials should test this innovative combination therapy.

Read More »

Safety and efficacy of the swift microwave device in patients with mild-to-moderate onychomycosis: Protocol of an open-label, randomized, dose-finding pilot study

mycolabadmin

This study evaluates a new microwave device (Swift System) as a potential treatment for fungal nail infections (onychomycosis). The device uses microwave energy to heat and eliminate fungal infections directly at the nail site, avoiding the side effects of oral medications. Researchers tested three different treatment schedules in 39 patients over 12 months to find the most effective dosing approach.

Read More »
Scroll to Top